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Abstract: Engineered nanomaterials have unique and 
novel properties enabling wide-ranging new applications 
in nearly all fields of research. As these new properties 
have raised concerns about potential adverse effects for 
the environment and human health, extensive efforts are 
underway to define reliable, cost- and time-effective, as 
well as mechanistic-based testing strategies to replace the 
current method of animal testing, which is still the most 
prevalent model used for the risk assessment of chemi-
cals. Current approaches for nanomaterials follow this 
line. The aim of this review is to explore and qualify the 
relevance of new in vitro and ex vivo models in (nano)
material safety assessment, a crucial prerequisite for 
translation into applications.
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Introduction
Pressure on nanomaterial [for a definition see box and 
(1)] safety comes from society, consumer and regulatory 
bodies, but also from industry to identify potential adverse 
nanomaterials as early as possible during development of 
nanomaterial-based products in order to avoid economic 
and social drawbacks. Multifunctional, smart or adap-
tive material concepts envisioned in nanomedicine, with 
an estimated worldwide market size of US$1 trillion (2), 
create new requirements for biological risk assessment. 
This in turn creates a demand for alternative test models 
which must be necessarily complex, but still as standard-
ized as possible to allow high throughput, content and 
cost-effectiveness (3), allowing the acceleration of ‘faster 
to fail’ processes (4).
In general, risk assessment of chemicals is mainly 
based on animal testing strategies – an approach that has 
not changed over the last 40 years (5). Current approaches 
for the risk assessment of nanomaterials follow very 
similar lines. However, this strategy is both resource- and 
time-consuming, leading to a bottleneck and a back-log of 
materials requiring testing (6). In addition, the number of 
newly-developed nanomaterial-based material concepts 
is steadily increasing. A full assessment of the safety of 
such materials following traditional regulations would 
be extremely cost-intensive and time-consuming. More-
over the outcome of animal testing regarding its predic-
tive power for human beings poorly correlated, due to 
physiological and biochemical species dissimilarities 
(7). Furthermore, the principle of the 3Rs – replacement, 
reduction and refinement – became an increasing public 
According to the European Commission, nanomaterials are 
defined as natural, incidental or manufactured (engineered) 
material-containing particles, in an unbound state or as an 
aggregate or agglomerate and where, for 50% or more of the 
particles in the number size distribution, one or more external 
dimensions is in the size range 1 nm–100 nm (1).
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and legal demand which for ethical reasons supports the 
replacement of animal use with more human-relevant 
alternatives (8). Therefore new concepts for efficient, 
cheaper and evidence-based testing strategies were pro-
posed, based on the use of human primary cells and cell 
lines (6).
In Switzerland more than 70 Mio CHF of public 
funds from the Swiss federation have been invested in 
research studies with animals, whereas  < 500,000 CHF 
have been made available for the development of alterna-
tive methods (9). A similar situation is reported for the 
EU. In the latest report, the use of 11.5 million animals 
was recorded for the year 2011, with rodents represent-
ing more than 80% of the total animal number (10). Con-
sequently, it is clearly time to realize a paradigm-shift 
towards the development of more complex and realistic 
in vitro alternatives.
Over the last 3–5 years, intensified efforts have been 
made towards a systematic development and evaluation of 
innovative and more reliable in vitro models in the hopes 
of improving R&D productivity in the pharmaceutical and 
biomedical industries. Thereby, the focus of this review is 
to explore and qualify the relevance of new human in vitro 
and ex vivo models in (nano)material safety assessment. 
Selected in vitro and ex vivo models are analyzed herein, 
and current challenges and perspectives associated with 
these approaches are further discussed, especially with 
regard to their ability to predict nanomaterial toxicity.
Human exposure to nanomaterials
Due to the enormous diversity of nanomaterials being pro-
duced and used in a wide variety of consumer, industrial, 
and biomedical applications, the exposure routes to which 
humans may be potentially subjected to nanomaterials 
are numerous. These specific routes include inhalation, 
injection, ingestion and permeation through (diseased) 
skin (11). The availability and toxicity of any nanomate-
rials to a biological organism is determined by both the 
toxicokinetics (TK) [administration, distribution, metabo-
lism and transformation and excretion (ADME)] and toxi-
codynamics (TD) (binding, interaction and induction of 
toxic effects) (12). As nanomaterials come into contact 
with the skin, the gastrointestinal or the respiratory tract, 
these biological compartments are “innately designed” to 
act as barriers to the passage of foreign materials into the 
organism (13). The epithelium provides a first interface 
between biological compartments, and after nanomate-
rials have passed through the epithelial barrier they may 
pass through the basement membrane and the subepi-
thelial connective tissue layer and eventually come into 
contact with endothelial cells lining the capillaries. As 
endothelial cells play an important role in inflammation 
processes (14), these nanomaterials might affect endothe-
lial cell function and viability, inducing pro-inflammatory 
stimuli. Biomedical application of nanomaterials requires 
most frequently the injection of these materials directly 
into the blood stream, bypassing the aforementioned clas-
sical barrier tissues. Aspects of blood-compatibility, liver- 
or nephrotoxicity or interactions with internal barrier 
tissues are thus becoming more relevant in nanomaterial 
safety assessment.
Towards predictive cell culture 
models of organs and barrier 
systems
The human body includes more than 200 different cell 
types with distinct levels of differentiation, embedded in 
soft extracellular matrices, organized in different tissues 
and organs, regulated by complex signalling networks 
and cross-talk (15). Due to this complexity, predictive 
models should mimic the key parameters of the in vivo 
organ. To achieve this, the following approaches are in 
development [adapted from (3)]:
i) replacement of malignant or cancer-derived cell lines 
by primary or well-characterized human cell lines
ii) movement from single cell type to multi-cellular 
cultures
iii) movement from monolayer to organoid-like 3D models
iv) tissue preparation from explants
What is still underestimated in the current cell-based 
models is the fact that living tissue in its correspond-
ing microenvironment is a dynamic and moving system 
(e.g., due to the bloodstream, lymph liquid or  breathing) 
or alternatively represent a particular interface (e.g., 
a barrier between different compartments such as air- 
liquid). These models would facilitate both the fundamen-
tal understanding of nanomaterial-biology interactions, 
elucidating specific mode-of-action mechanisms, as well 
as translational research aimed at accelerating the market 
readiness of nanomaterial-based innovations. These 
reflections are addressed and consistently emphasized 
in a number of reports and reviews on the subject (4, 16, 
17) and are attracting increasing attention in the scientific 
community.
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Human alternative models
Cell-based in vitro models: the bottom up 
approach
Since the discovery of the possibility of maintaining 
animal tissues and cells in artificial media outside of the 
organism in glass dishes (in vitro) in the late 19th century 
(18), several key inventions have been made, such as the 
establishment of the first human carcinoma cell line HeLa 
(19), the production of monoclonal antibodies by cell 
fusion of mouse myeloma cells with lymphocytes origi-
nating from the spleen (20), or the development of a com-
plete cell culture medium such as Dulbecco’s modified 
Eagle medium developed by Harr Eagle and Renato Dul-
becco (21). These achievements in cell culture technology 
significantly boosted not only the fields of virology and 
cell-transfection technology in recent decades, but also 
stem cell research, and have become indispensable tools 
in modern biomedical research.
Over the last 10 years, well-characterized cells either 
freshly isolated from tissue (primary cells) or cell lines 
were used as building blocks for co-culture systems or 
three-dimensional micro-tissues (22, 23). An impor-
tant step forward in this field was the development 
of permeable supports that allow researchers to keep 
the culture medium on either side of the cultured epi-
thelium  separate, leading to increased differentiation 
of the cultured cells (24) or the growth of different cell 
types on two sides of the membranes (25, 26). Further-
more, the medium can be removed from the upper side 
to expose the cells to (for example) air on one side, and 
to allow them to be fed from the medium in the chamber 
 underneath (27).
These advanced in vitro cultures close the obvious gap 
between monolayer cultures and animal models, combining 
the advantages for increased throughput capabilities and 
increased predictive power. However, most of these systems 
are still in their infancy and further validation is needed in 
terms of reliability, relevance and predictive power.
A number of promising examples have been published 
that carefully address physiological relevance, correlation 
and validation against established in vivo models. The 
respiratory tract, being the most sensitive entry port of 
nanomaterials, has been the focus of several hundred in 
vitro and in vivo studies [for reviews see (28–30)]. There-
fore, it is not surprising that human advanced in vitro 
models have been developed in order to gain more insight 
into the mode of action of inhalable aerosols/(nano)parti-
cles (Figure 1A, B).
Many monocultures exist that mimic the different 
compartments of lungs, i.e., conducting airways and lung 
parenchyma, however, the advantage of co-cultures in 
this research area was already recognized several years 
ago. The first two co-culture systems were described using 
epithelial and endothelial cells to study the impact of nan-
oparticles (26, 31).
We recently reported on an in vitro triple-cell co-cul-
ture model of the human airway wall composed of three 
main cell types: epithelial cells, human blood monocyte-
derived macrophages and dendritic cells cultivated in a 
transwell system (32). A detailed characterization and val-
idation of the system showed that the cell-cell interactions 
and communication in the culture system behave similar 
to that in vivo, indicating not only the proper functioning 
Figure 1: Examples of conventional cell culture models and ex vivo models. Laser scanning micrographs representing epithelial monocul-
tures (A549 lung epithelial type II cell line) labelled for F-actin (green) and cell nuclei (white) (xy projection) (A); co-cultures of epithelial cells 
forming a tight monolayer (white) with macrophages on top (orange, arrows) (3D shadow projection with transparent renderings) (B), and a 
precision cut slice from rat lungs stained for F-actin (red) and macrophages (green, arrows) (C).
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but also improved biological relevance of the system 
(29). Further improvements with four cell types were also 
described recently, showing that epithelial and endothe-
lial cells, macrophages, and mast cells (33, 34) can be cul-
tured together to study the impact of both engineered and 
environmental particles.
Liver- and nephrotoxicity profiles of nanomaterials 
used as carriers in nanobiomedical applications must be 
well defined since the materials have direct access to those 
organs when injected into the bloodstream. Nanomate-
rial biodistribution studies elaborated in animal studies 
show a significantly high accumulation in the mononu-
clear phagocyte system (MPS) (35). The liver, a multifunc-
tional organ of the digestive system, plays a central role 
in homeostasis and detoxification of foreign substances 
(including nanomaterials) reaching the bloodstream (36). 
A number of in vitro approaches including two- (2D) and 
three-dimensional (3D) systems used to assess hepatotox-
icity were summarized in great detail by Godoy and col-
leagues in 2013 (37). In short, significant differences were 
observed in the response of hepatocytes after treatment 
with different drug substances depending on whether 
the cells were cultivated in monolayers or as 3D cultures, 
indicating the importance of the model system on the bio-
logical effect assessment. Another recent report shows 
the potential of 3D liver microtissue models generated 
by primary hepatocytes for the toxicology assessment 
of nanomaterial exposures (38). Although promising 3D 
systems have been reported, the majority of the hazard 
assessments of nanomaterials to date have still involved 
hepatocyte monocultures, probably due to lack of clear 
guidance or validated advanced human in vitro systems.
The kidney, with its central role in metabolism and 
blood filtration, is continuously exposed to adverse metab-
olites, drugs or nanoparticles, and therefore must be con-
sidered in safety assessment. A recent study developed a 
3D organoid kidney proximal tubule epithelial cell system 
based on isolated proximal tubules from male C57BL/6 
mice cultivated in hyaluronic acid hydrogels (39, 40). 
Well-defined fluorescein isothiocyanate (FITC)-labelled 
carboxyl-terminated poly(amidoamine) (PAMAM) dendrim-
ers  < 6 nanometers in diameter were applied to consider an 
in-depth in vitro - in vivo correlation study. These dendrim-
ers produced a set of toxicity indicators which accurately 
reflected the damage observed in vivo (41), indicating high 
predictive power of the system for nephrotoxicity. Further 
extension to disease models or human proximal tubules 
would help to strengthen this promising approach.
Despite all the advantages described in these exam-
ples, advanced in vitro systems have become more and 
more time- and cost-intensive, and well-trained experts 
are also needed to work with complex cell culture systems, 
all issues that should not be neglected. Therefore, ex vivo 
tissue preparation might present a viable alternative 
approach to obtain predictive model systems.
Ex vivo tissue preparation: bringing in vivo 
tissue into Petri dishes
A promising alternative approach that provides a better 
in vivo-like environment is the use of precision-cut tissue 
slices (PCS), which represent an ex vivo model of the organ 
of study by maintaining the original architecture, i.e., con-
taining all the cells types of the tissue in their natural con-
formation (42). The advantage of this system is that slices 
from different species can be prepared and compared, such 
as from rodents as well as human biopsy material. Particu-
larly impressive progress towards this end has recently been 
made in the field of lung research [for a review see (43)]. 
Although most studies have focused on aspects of pharma-
toxicology (44, 45), some recent publications have proven 
that PCS-based approaches are highly relevant for the risk 
assessment of nanomaterials and xenobiotics in general, in 
terms of inflammation, organ injury and sensitization (46–
48). A recently published study showed, however, that the 
system might only be useful for ions released from nano-
particles or soluble substances since it was observed that 
the silver nanoparticles did predominantly attach at the cut 
surfaces of the PCS from lung tissues (Figure 1C) but could 
hardly penetrate into deeper regions (49).
Fewer studies have been published using liver PCS 
to assess the interaction of nanomaterials with the organ 
slices (50, 51). The disadvantage of this technique is that 
by cutting the organ into slices the surface is covered with 
damaged cells, which might themselves induce an inflam-
matory reaction. However, in general, this system has 
great potential and warrants further exploration.
Regardless of the chosen approach (bottom up or 
ex vivo), the balance between relevant output data and 
throughput capability has to be evaluated carefully. Not 
only throughput suitability but also the development of 
high content analysis applicable to advanced in vitro as well 
as ex vivo models should be considered to be able to gain 
further mechanistic understanding in (nano)material safety 
assessment [see also Ref (52) for more detailed insight].
Organs-on-chip approaches
Innovative in vitro platforms based on microfluidic tech-
nologies and aimed at assessing nanomaterial safety 
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and efficacy are currently emerging [for a review see 
(53)]. These systems, called “organs-on-chip” (54, 55), 
intend to mimic the physiological conditions and archi-
tecture of human tissues. 3D organoids made of human 
cells are created on bioengineered platforms in order to 
simulate key organ-level functions (56). These systems, 
which mimic the in vivo environment of specific organs 
in an unprecedented way, are widely seen as having the 
potential to improve in vitro model accuracy and experi-
mental efficiency. Although most of the ongoing efforts 
target the development of more predictive preclinical in 
vitro models (57), the potential of these devices for toxi-
cology evaluation of chemicals, such as nanomaterials, is 
undisputable.
One of the key assets of these novel technologies is 
their capability to accurately reproduce specific aspects of 
the cellular microenvironment of various tissues. They not 
only enable the creation of microstructures with dimen-
sions that are similar to those of mammalian cells, but 
also allow control of the cellular microenvironment in 
space and time. The perfusion of cell cultures confined 
in such systems enables them to mimic the continuous 
transport of nutrients and oxygen, the dilution of the 
secreted cytokines and chemokines, in addition to the cel-
lular waste products (58). Insoluble signals can also be 
reproduced by modifying the cell culture surface topogra-
phy or stiffness, and/or by the addition of specific extra-
cellular matrices (59). Mechanical stimuli, such as the 
cyclic mechanical strain of respiration movements, are 
additional and important factors that affect the cellular 
and organ homeostasis (60).
Microfluidic technologies offer further possibilities to 
recreate the cell microenvironment, including the integra-
tion of cell culture membranes in microfluidic chambers, 
allowing for the creation of bioartificial barriers. Micro-
fluidic barriers have recently been reported to recreate a 
number of in vivo barriers, such as the liver sinusoidal 
barrier (61), the blood-brain barrier (62, 63), and the gut 
(64), to name just a few.
Microfluidic air-liquid interfaces mimicking the 
alveolar barrier using porous membranes have also been 
described. Nalayanda and colleagues reported a perfused 
lung alveolar epithelial layer cultured on a PET porous 
membrane (65), whereas Zheng et  al. (66) investigated 
the mechanical stresses induced by liquid plug propa-
gation in a similar airway model. Recently, even more 
sophisticated lung alveolar models were reported that 
were able to mimic the mechanical processes of physi-
ological breathing and the shear stress induced by the 
blood stream. Douville et al. (67) reported a microfluidic 
chip equipped with a 100 μm-thick poly(dimethysiloxane) 
Figure 2: Example of an organ-on-chip: A lung-on-a-chip made of 
an array of three lung alveoli with a thin, alveolar barrier that can be 
 cyclically stretched to mimic the respiration movements. Scale bar 
5 mm.
(PDMS) membrane on which epithelial cells were cultured 
and cyclically stretched. This microfluidic alveolar model 
allowed the recreation of the fluid and solid mechanical 
stresses taking place in the alveoli during mechanical 
ventilation. In contrast to the latter model, Huh et al. (68) 
reported an innovative “breathing” lung-on-a-chip device 
in which the air-liquid interface was reproduced, with a 
10  μm-thin, porous PDMS membrane on which epithelial 
and endothelial cells were cultured. In an experiment in 
which the epithelium was exposed to 12 nm silica nano-
particles, evidence was obtained that “breathing” motions 
greatly accentuate the pro-inflammatory activities of silica 
nanoparticles. Furthermore, it was demonstrated that 
translocation of these nanoparticles across the alveolar-
capillary interface was significantly increased in mechan-
ically-stressed alveoli in comparison with static controls. 
Very recently, a novel lung alveolar barrier model was 
reported consisting of a 3.5 μm thin, porous and flexible 
membrane on which epithelial and endothelial cells were 
cultured and whose actuation mechanism is inspired by 
the lung diaphragm contraction (Figure 2). A permeability 
assay carried out with this advanced model revealed that 
the permeability of small hydrophilic molecules (FITC-
Na+) was significantly increased if the cells were mechani-
cally and cyclically stretched. In contrast, no significant 
effect was observed for a larger molecule [rhodamine B 
isothiocyanate-dextran (RITC-dextran)](69). These results 
are comparable to an in vivo study (70) that showed a 
higher clearance of hydrophilic solute upon increasing 
the human lung volume, suggesting that the novel lung 
alveolar barrier model better mimics the in vivo situation 
than existing in vitro models.
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Although the expectations in the potential of such 
approaches are very high, their development is still in their 
infancy. More validation steps will be required to identify 
their unique possibilities and the benefits of reproduc-
ing organ-level functions (e.g., breathing movements). 
One of the key factors that will need to be improved is the 
shift towards more relevant cells (e.g., primary cells) from 
the cell lines that are still broadly used in such models. 
Once these requirements are fulfilled such models may 
well provide low-cost alternatives to animal and clinical 
studies for faster and more efficient drug screening and 
material toxicological testing.
Qualification of reliable and 
accurate in vitro models
The early results of 2D model systems assessing the toxic-
ity of nanomaterials were often contradictory, for several 
reasons that were outlined in a number of publications over 
the last few years (71–75), and lacked in vitro - in vivo cor-
relation. The reasons can be summarized into five groups:
(i) no correlation between simple in vitro models and in 
vivo measurements (39–41)
(ii) no informative assay controls documenting the per-
formance characteristics of the model system (76)
(iii) no adequate calculation of the applied dosages of 
nanomaterials
(iv) absence of appropriate interference controls uncover-
ing potential interference between nanomaterials and 
the detection system (73)
(v) absent or incomplete characterization of nano-
materials (71)
The first reason (i) illustrates the poor relevance of 
common in vitro cell assays for the assessment of acute 
toxic effects of nanomaterials on full biological organisms. 
Furthermore, recent results of an interlaboratory compari-
son underline that the last four aspects (ii–v) are impor-
tant in obtaining an adequate comparability between the 
results of the different participating laboratories.
A number of recent studies illustrate that basic 2D 
cell culture models lack a reasonable correlation with 
in vivo studies (39–41). Therefore their predictability 
and relevance is also poor. At the same time the correla-
tion between rodent models and humans is around 60% 
(77), which leads to some augmented risk in early clinical 
trials. Recently published results demonstrate some cor-
relation between advanced 3D cell culture systems and 
in vivo models (39–41). This highlights the importance 
of the adequacy of the selected model systems and their 
qualification with respect to reliability and accuracy. In a 
number of instances it proved difficult to determine the 
reasons for the poor comparability of common cell assays 
used for nanotoxicity assessments, as the controls were 
inadequate to document proper functioning of each step 
of an experimental procedure. A cause-and-effect analysis 
was an effective tool to categorize the various influences 
affecting the performance of common MTS cell prolifera-
tion assays (78). Based on this outline, a number of con-
trols that monitor the assay performance for the different 
steps of the procedure were integrated into the design of 
the standard 96-well plate. Results of a recent interlabora-
tory comparison showed the combined strength of these 
controls to uncover potential shortcomings in the stand-
ard operating procedure (unpublished observations, Dr. 
Matthias Roesslein). In addition, the full titration of the 
chemical positive control and the deduced EC50 value 
that is within tight specifications allows for documenta-
tion of the proper functioning of the entire assay itself for 
each experiment. This enables comparability within and 
between laboratories over a longer period of time. The 
six major categories of a cause and effect analysis, such 
as cell maintenance, pipetting, instrument performance, 
toxic chemical positive control, assay protocol, and engi-
neered nanomaterial handling and characterization, will 
also help in determining most influences of advanced 3D 
cell culture systems. This systematic summarization of 
effects facilitates the overview of functional principles of 
even complex cell culture systems. Furthermore, it allows 
the design of adequate controls that document their per-
formance characteristics, in particular the EC50 value 
chemical positive control.
Until the publication of the in vitro sedimentation, 
diffusion and dosimetry (ISDD) model in 2010 (76), there 
was only a limited understanding of the actual dosing 
levels of nanomaterials during nanomaterial-cell inves-
tigations using adhesive cell culture assays. With all rel-
evant information stated in the publications, this allows 
conversion of the common weight/volume as the dosing 
unit of the nanomaterials to the actual number of particles 
interacting with the cells over the duration of the experi-
ment. Even at the early stage of any advanced models, the 
calculation of the proper dosing of the investigated nano-
materials is examined and potential scenarios have been 
outlined. The model has been extended by Rodriguez- 
Lorenzo and colleagues, who included heterogeneity, 
including polydispersity both in size and mass density to 
study the influence of heterogeneity on the particokinetics 
of nanoparticles and on the corresponding delivered dose 
(79). Therefore it will be essential that at least a full set of 
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dosing-relevant characteristics is given in a publication so 
that in the future a direct comparisons of results of the dif-
ferent approaches is feasible.
Interference controls will require further optimiza-
tions, as the readout system of any endpoint in a co-cul-
ture or advanced 3D model system will be refined due to 
the more complex structure of these systems compared to 
a simple adhesive cell culture. In addition, basic materials 
characterization of any nanomaterial remains essential, 
regardless of the applied type of in vitro or ex vivo model 
system (71).
Regulatory environment
This review focuses on the scientific issues, the possibilities 
and limitations of advanced in vitro – and ex vivo model 
systems established to date for the risk assessments related 
to nanomaterial exposure. It summarizes the models that 
may one day have to qualify for the regulatory review and 
some unresolved questions about a “fit for purpose” solu-
tion within the current regulatory framework. Two differ-
ent regulatory frameworks address the specific objectives 
of industrial and medical applications. Industrial nano-
materials are regulated under the REACH and OECD guide-
lines following the tracks of chemicals with toxicity testing 
for product fillings. In addition, within the EU there are 
considerable efforts to replace the expensive and contro-
versial discussed animal testing with in vitro alternatives 
(5–7). Despite the fact that changing this regulation is a 
long process, first efforts have been successful within the 
EU with a ban on animal testing for skin allergies of cosmet-
ics (80). In contrast, the regulatory environment of medical 
related nanomaterials is highly fragmented with individual 
national regulations. The testing strategy of the pharma-
ceutical industry focuses mainly on avoiding failure during 
clinical trials and their tremendous costs. Therefore they 
have a considerable interest in novel in vitro models able to 
better predict the clinical outcome.
Conclusions
Due to the inevitable exposure of nanomaterials to 
humans it is imperative to gain an understanding of how 
these materials interact with the human body, since there 
are increasing concerns as to the potential adverse effects 
on human health that the production of, and subsequent 
exposure to, such nanomaterials might pose. In the field 
of regulatory toxicology, animal testing is still the most 
Assay
performance
Interference & Material
characterization
In Vitro & In Vivo
Mechanistic
understanding
Dosage
Nanomaterial
assessment
Figure 3: Important components that allow to link nanomaterial 
assessment with mechanistic understanding in a biological system 
in a reliable way.
prevalent model used for risk assessment. It is, however, 
time to realize that a paradigm-shift in the understanding 
of toxicology towards a modern evidence-based research 
discipline can be supported by advanced in vitro and ex 
vivo models. It has already been recognized that in vitro 
and ex vivo models should be able to depict the complexity 
of an organ or tissue as far as possible, while maintaining 
the capability for standardization, high throughput and 
reproducibility. In addition the relevance of these models 
has to be validated towards animal models and especially 
towards human related epidemiological studies for nano-
materials exposure. Furthermore clinical trials will be 
needed to assess the relevance of theses novel models for 
nanomaterials to be used for medical purpose.
Extensive efforts have been made to simulate differ-
ent organs in a petri dish, and predictive cell culture or ex 
vivo models have been generated. It will require, however, 
a combined effort of many disciplines to focus more on 
the reliability of such systems by considering the thor-
ough characterization of nanomaterials, but also the cell 
culture systems. In addition, validation with well-known 
toxic substances should be emphasized in order to gain a 
proof-of-concept.
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